AECOM Share Price Target ‘$108.56’, now 21.2% Upside Potential

DirectorsTalk Interviews

AECOM with ticker code (ACM) have now 9 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The range between the high target price and low target price is between $116.00 and $100.00 calculating the mean target share price we have $108.56. (at the time of writing). Given that the stocks previous close was at $89.57 and the analysts are correct then we can expect a percentage increase in value of 21.2%. Also worth taking note is the 50 day moving average now sits at $93.99 and the 200 day MA is $88.35. The total market capitalization for the company now stands at 12.27B. The stock price is currently at: $90.14 USD

The potential market cap would be $14,871,991,066 based on the market consensus.

The company has a dividend yield of 0.03%. Other points of data to note are a P/E ratio of 103.61, revenue per share of $111.89 and a 4.65% return on assets.

AECOM is a global provider of professional infrastructure consulting services for governments, businesses, and organizations across the world. The Company operates through three segments: Americas, International, and AECOM Capital (ACAP). The Americas segment provides planning, consulting, architectural and engineering design, and construction and program management services to commercial and government clients in the United States, Canada, and Latin America in end markets, such as transportation, water, government, facilities, environmental, and energy. The International segment offers planning, consulting, architectural and engineering design services and program management to commercial and government clients in Europe, the Middle East, Africa and the Asia-Pacific regions in end markets, such as transportation, water, government, facilities, environmental, and energy. The ACAP segment invests primarily in and develops real estate projects.

Share on:
Find more news, interviews, share price & company profile here for:

    HUTCHMED showcases new oncology data at ASCO 2025

    HUTCHMED (China) Limited is set to unveil groundbreaking data on key cancer therapies at the 2025 ASCO Annual Meeting, highlighting promising advancements in NSCLC and solid tumors.

    Ilika launches £3.8m fundraise including £0.5m Retail Offer

    Ilika Plc has successfully closed its accelerated bookbuild, raising approximately £3.3 million to enhance solid-state battery technology and commercial growth.

    Nuformix raises £210,000 to advance NXP002 and US Orphan Drug Application

    Nuformix plc (LON:NFX) aims to raise £210,000 through a conditional placing to advance its NXP002 inhalation treatment for IPF and PPF.

    Likewise grants over 3.1m shares under 2025 SAYE scheme

    Likewise Group plc (LON:LIKE) has successfully closed its 2025 Save As You Earn Scheme, granting options to 69 employees on over 3.1 million shares.

    Zotefoams reports record £50.7m revenue in strong start to 2025

    Zotefoams Plc reports strong sales growth of 8% and record revenue for the first four months of 2025, showcasing a successful strategic pivot into key markets.

    Ilika announces £3.5m fundraise via Placing and Retail Offer

    Ilika Plc, a leader in solid-state battery technology, plans to raise approximately £3.0 million through a new share placing and a retail offer for shareholders.

      Search

      Search